CSIRO says it welcomes public discussion about the ethics of Artificial Intelligence (AI) following the release of 'Artificial Intelligence: Australia’s Ethics Framework'.
The discussion paper, developed by CSIRO’s Data61, is designed to encourage a conversation on how Australia will develop and uses AI.
"It identifies key governance principles and measures that can be used to achieve the best possible results from AI, while keeping the well-being of Australians as the top priority," said CSIRO in a statement.
According to CSIRO chief executive, Dr Larry Marshall, as AI is increasingly used in homes, workplaces and communities, Australia must ensure it transforms industries and creates new jobs in the right way.
“As Australia’s national science agency, a focus on ethics, social licence to operate, and clear national benefit have always determined how we apply science and technology to solve Australia’s greatest challenges,” said Dr Marshall.
“The draft framework contextualises these age-old ethical considerations in the light of new technology, so everyone can have a say in inventing the future we need so our children can keep pace with emerging technologies like AI.”
Adrian Turner, CEO at CSIRO’s Data61, said AI is already here and developing quickly.
“AI represents a powerful general purpose technology that will help Australia solve some of our biggest problems relating to energy, health, ageing, safety, security, climate and the environment.”
“However, we will only realise this potential if we address underlying science and technology challenges in AI itself as well as its implications for people.
"Because of the deep influence AI will have on us all, we need to ensure that these systems work for us and deliver benefits individually and collectively.
"The AI ethics framework identifies principles and tools for achieving this in practice,” said Mr Turner.
New Stories
-
How venture capital can unlock biotech’s long-term value
July 23, 2026 - - Latest News -
CLINUVEL to move headquarters to US and restructure workforce ahead of new listing
July 23, 2026 - - Latest News -
BLS and Trexapharm move to bring TREXAVIVE to Australian patients
July 23, 2026 - - Latest News -
Radiopharm Theranostics reports positive results in tumour trials
July 23, 2026 - - Latest News -
Proteomics International and Healius team up to take Promarker tests national
July 23, 2026 - - Latest News -
PYC Therapeutics reveals sustained gene expression and vision gains in ADOA trials
July 21, 2026 - - Latest News -
Syntara trial moves to final Phase 1b dose as German sites open for recruitment
July 21, 2026 - - Latest News
